Corcept Therapeutics (CORT) Other financing activities (2015 - 2026)
Corcept Therapeutics (CORT) posted Other financing activities of $5.8 million for Q2 2026, up 44.5% sequentially from $4.0 million in Q1 2026, and down 37.66% YoY from $9.2 million in Q2 2025.
Corcept Therapeutics (CORT) Other financing activities (2015 - 2026) Analysis & Trends
Corcept Therapeutics has reported Other financing activities for 6 years, with the latest figure at $5.8 million in Q2 2026.
- Quarterly Other financing activities fell 37.66% year-over-year to $5.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $14.6 million (up 6.08% YoY) and the FY2025 annual result came in at $15.9 million, up 190.69% from the prior year.
- Other financing activities climbed to $5.8 million in Q2 2026 per CORT's latest filing, from $4.0 million in the prior quarter.
- Over five years, Other financing activities peaked at $9.2 million in Q2 2025 and troughed at $704000.0 in Q3 2023.
- A 4-year average of $2.5 million and a median of $1.6 million in 2024 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2025 and 2026: Other financing activities soared 443.88% in 2025, then tumbled 37.66% in 2026.
- Over 4 years, Other financing activities stood at $875000.0 in 2023, then soared by 75.09% to $1.5 million in 2024, then soared by 86.75% to $2.9 million in 2025, then soared by 101.22% to $5.8 million in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $5.8 million, $4.0 million, and $2.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.76 Mn |
| Jun 30, 2026 | 5.76 Mn |
| Mar 31, 2026 | 3.98 Mn |
| Mar 31, 2026 | 3.98 Mn |
| Dec 31, 2025 | 2.86 Mn |
| Dec 31, 2025 | 2.86 Mn |
| Sep 30, 2025 | 2.03 Mn |
| Sep 30, 2025 | 2.03 Mn |
| Jun 30, 2025 | 9.24 Mn |
| Jun 30, 2025 | 9.24 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.29 Mn |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 940,000.00 |
| Mar 31, 2024 | 940,000.00 |